Medicine and Dentistry
Biochemical Recurrence
7%
Biopsy Technique
8%
Bladder
17%
Bladder Cancer
48%
Cancer Cell
6%
Carbon 11
8%
Castration Resistant Prostate Cancer
6%
Choline
8%
Clear Cell Renal Cell Carcinoma
7%
Clinical Trial
6%
Computer Assisted Tomography
9%
Cystectomy
35%
Diseases
18%
Family History
8%
Gallium 68
14%
Immune Checkpoint Inhibitor
5%
Immunotherapy
12%
Kidney Metastasis
9%
Lymph Node
28%
Lymph Node Metastasis
12%
Magnetic Resonance Imaging
8%
Malignant Neoplasm
17%
Metastatic Carcinoma
14%
Muscle Invasive Bladder Cancer
9%
Neobladder
9%
Neoplasm
30%
Nivolumab
6%
Oncology
7%
Overall Survival
9%
Pelvis
12%
Polyethylene Terephthalate
11%
Positron Emission Tomography
16%
Positron Emission Tomography-Computed Tomography
11%
Prostate Cancer
100%
Prostate Specific Antigen
14%
Prostate Specific Membrane Antigen
21%
Prostatectomy
39%
Quality of Life
7%
Radiation Therapy
15%
Radiosurgery
8%
Recurrent Disease
15%
Retroperitoneal Lymph Node Dissection
18%
Sunitinib
6%
Survival Rate
6%
Systemic Therapy
12%
Transitional Cell Carcinoma
26%
Urinary Diversion
5%
Urologist
7%
Urology
9%
Urothelial Cancer
11%
Keyphrases
Apoptosis
6%
Biochemical Recurrence
6%
Biochemical Recurrence-free Survival
8%
Bladder Cancer
43%
Bone Metastasis
7%
Cancer Patients
10%
Castration-resistant Prostate Cancer
7%
Chemotherapy
14%
Clinical Trials
6%
Confidence Interval
9%
Cystectomy
11%
Docetaxel
8%
Everolimus
9%
Family History
7%
Germany
13%
High Risk
10%
Immune Checkpoint Inhibitors
6%
Invasive Urothelial Carcinoma
7%
Lymph Node
12%
Lymph Node Metastasis
13%
Metastasis
7%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
20%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Metastatic Renal Cell Carcinoma (mRCC)
19%
Muscle-invasive Bladder Cancer
9%
Nivolumab
7%
Overall Survival
14%
Pazopanib
8%
Phase II Trial
7%
Positron Emission Tomography
10%
Prednisone
7%
Prostate
7%
Prostate Cancer
61%
Prostate Cancer Patients
18%
Prostate Cancer Survivors
7%
Prostate-specific Antigen
34%
Radical Cystectomy
28%
Radical Prostatectomy
39%
Radioguided Surgery
8%
Recurrent Prostate Cancer
13%
Renal Cell Carcinoma
9%
Salvage Radiotherapy
7%
Sunitinib
11%
Systemic Therapy
7%
Tumor
17%
Upper Tract Urothelial Carcinoma
9%
Urologists
7%
Urology
9%
Urothelial Cancer
9%
Urothelial Carcinoma
7%